Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for symptomatic diastolic heart failure
ISRCTN94726526Phase 2Completed
- Sponsor
- Georg-August-Universität Göttingen
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Spironolactone with Placebo (2 arms). Primary endpoints: Change in maximum exercise capacity and Change in diastolic filling pressure surrogate. Started Nov 2006; status: completed.
02
Drugs
spironolactone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on ISRCTN94726526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN94726526.